Processa Pharma Stock (NASDAQ:PCSA), Trade Ideas

Processa Pharma

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Long Ideas

News

Penny Stocks

Small Cap

Insider Trades

Markets

Trading Ideas

ABEO

PCSA

The Dow Jones index closed higher by around 150 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Processa Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying

Pre-Market Outlook

CATX

EXFY

The Dow Jones index closed higher by more than 350 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Expensify And 3 Other Stocks Under $3 Insiders Are Buying

PAYS

RLMD

The Dow Jones index closed lower by more than 300 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Relmada Therapeutics And 2 Other Penny Stocks Insiders Are Buying

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals Inc

MRNA

Moderna To Present Data From Its Respiratory Portfolio, Including Vaccines And Vaccine Candidates, And Cytomegalovirus Research At ESCMID Global Congress

The accounting firm founder contracted by Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) Ben F Borgers, reportedly has been found to have used 14 different versions of his name in regulatory filings.
What Happened: BF Borgers, the accounting firm run by Borgers, is responsible for auditing the finances of Trump Media &amp; Technology Group. The Financial Times reviewed public documents and <a href="https://www.ft.com/content/2556fab5-d168-4d68-aedb-9be4b5ab739d">reported</a> that Borgers&#8217; name has appeared in filings in various forms, including Ben F Brogers, Blake F Borgers, Ben F Vonesh, and Ben F Orgers, among others. Some of these variations appear to be simple spelling errors.
Such spelling inconsistencies are not common among auditors. 
These irregularities could potentially cast doubt on the standards of Borgers&#8217; firm, as per Agnes Cheng, a professor of accounting at the University of Oklahoma. 
&#8220;If multiple names are due to careless mistakes and lack of attention, then how can we trust him concerning his attention to the audits that he has to supervise,&#8221; she said.
BF Borgers did not immediately respond to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga's</a> request for comment.
See Also: <a href="https://www.benzinga.com/news/24/04/38349837/elon-musk-agrees-every-american-household-will-have-a-1-000-per-month-home-robot-in-7-years-time?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Agrees Every American Household Will Have A $1,000-Per-Month Home Robot In 7 Years&#8217; Time</a>
Why It Matters: This news comes on the heels of <a href="https://www.benzinga.com/markets/equities/24/04/38410320/stock-manipulation-in-trump-media-technology-group-stock-ceo-devin-nunes-urges-house-gop-leaders">allegations of stock manipulation</a> in Trump Media &amp; Technology Group, with CEO Devin Nunes urging House GOP leaders to investigate. 
Furthermore, former President Donald Trump is set to <a href="https://www.benzinga.com/general/politics/24/04/38362005/donald-trump-may-soon-receive-36-million-more-djt-shares-key-milestone-ahead">receive an additional $1.26 billion worth</a> of shares in the company if it meets certain performance-based milestones, as per the original SPAC merger agreement with Digital World Acquisition Corporation.
Price Action: Trump Media &amp; Technology Group Corp closed at $35.67 on Wednesday, a 9.52% increase from the previous close, according to <a href="https://pro.benzinga.com">Benzinga Pro</a>.
Read Next: <a href="https://www.benzinga.com/markets/equities/24/04/38368953/jim-cramer-sees-nvidia-as-going-from-star-of-the-show-to-being-the-goat-of-the-game?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Jim Cramer Sees Nvidia As Going &#8216;From Star Of The Show To Being The Goat Of The Game&#8217;</a>
Photo via Shutterstock.
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by Benzinga Neuro, Edited by 
 <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Pooja Rajkumari</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>
</div>

Equities

General

Trump's Social Media Company Auditor Misspells Own Name 14 Times In Regulatory Filings: Report

<ul>
<li>Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8&micro;L spray per eye)</li>
<li>Also announces upcoming ARVO presentation on the unique technology behind clobetasol that allows for future ophthalmic suspensions to be dispensed with the Optejet.</li>
</ul>

Biotech

Health Care

EYEN

Eyenovia Provides Clinical and Scientific Update On FDA-Approved Products Mydcombi And Clobetasol Propionate Ophthalmic Suspension

WIIM

IBRX

ImmunityBio shares are trading higher after the company announced overall survival results in its QUILT 3.055 study.

Guidance

HOUS

Anywhere Real Estate Sees FY24 Cost Savings Of At Least $100M

Guidance&nbsp;for full-year 2024, notwithstanding further changes in the operating environment, is as follows:
<table border="0" cellpadding="0" cellspacing="0">
<tbody>
<tr>
<td>
●
</td>
<td>
Sales to be in the range of&nbsp;$850 million&nbsp;to&nbsp;$900 million; Assumes no Blue Arc EV revenue
</td>
</tr>
</tbody>
</table>
<table border="0" cellpadding="0" cellspacing="0">
<tbody>
<tr>
<td>
●
</td>
<td>
Adjusted EBITDA of&nbsp;$40&nbsp;to&nbsp;$50 million, including EV spending of&nbsp;$20&nbsp;to&nbsp;$25 million
</td>
</tr>
</tbody>
</table>
<table border="0" cellpadding="0" cellspacing="0">
<tbody>
<tr>
<td>
●
</td>
<td>
Net income of&nbsp;$2.5&nbsp;to&nbsp;$10.5 million, with an income tax rate of approximately&nbsp;20%
</td>
</tr>
</tbody>
</table>
<table border="0" cellpadding="0" cellspacing="0">
<tbody>
<tr>
<td>
●
</td>
<td>
Earnings per share of&nbsp;$0.07&nbsp;to&nbsp;$0.30
</td>
</tr>
</tbody>
</table>
<table border="0" cellpadding="0" cellspacing="0">
<tbody>
<tr>
<td>
●
</td>
<td>
Adjusted earnings per share of&nbsp;$0.28&nbsp;to&nbsp;$0.51
</td>
</tr>
</tbody>
</table>
<table border="0" cellpadding="0" cellspacing="0">
<tbody>
<tr>
<td>
●
</td>
<td>
Capital expenditures of approximately&nbsp;$20&nbsp;to&nbsp;$25 million
</td>
</tr>
</tbody>
</table>
<table border="0" cellpadding="0" cellspacing="0">
<tbody>
<tr>
<td>
●
</td>
<td>
Free cash flow of&nbsp;$25&nbsp;to&nbsp;$35 million
</td>
</tr>
</tbody>
</table>
Dunn concluded, &ldquo;Shyft has industry leading&nbsp;

SHYF

The Shyft Group Reiterated FY24 Adj EPS $0.28-$0.51 Vs $0.39 Est and Sales $850M-$900M Vs $864M Est.

Are you tired of the same old snacks filling your pantry shelves? Sometimes, a little change can add a delightful twist to your daily nibbles. From the earthy tones of Matcha Kit Kat to the fizzy kick of Cherry Cola, we&#8217;re diving into some of the most audacious snack alternatives out there. Let&#8217;s explore if these tantalizing tweaks are worth a taste!
Matcha Kit Kat
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25020253/image-189-1024x585.png" alt="" class="wp-image-307892" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25020253/image-189-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25020253/image-189-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25020253/image-189-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25020253/image-189-1536x878.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25020253/image-189.png 1792w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Forget the classic milk chocolate Kit Kat and try out the Matcha variety: Image Generated Via Dall-E</figcaption></figure>
Forget the classic milk chocolate Kit Kat and say hello to its much greener cousin, Matcha Kit Kat. Originating from Japan, this snack infuses the subtle, yet rich, flavors of matcha green tea into the creamy chocolate layers. It's a perfect blend of East meets West, offering a refreshing twist that might just convert you from the traditional version. Ideal for those who enjoy a touch of bitterness balanced with sweetness!
See Also: <a href="https://www.benzinga.com/news/24/04/38368085/what-happens-if-trump-gets-convicted-will-he-go-to-prison-heres-how-it-likely-to-play-out?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">What Happens If Trump Gets Convicted? Will He Go To Prison? — Here&#8217;s How It&#8217;s Likely To Play Out</a>
Cherry Cola
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25015044/image-188-1024x585.png" alt="" class="wp-image-307870" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25015044/image-188-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25015044/image-188-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25015044/image-188-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25015044/image-188-1536x878.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25015044/image-188.png 1792w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Cherry Coke is a favorite in summer time, it offers a refreshing alternative to the classic variety: Image Generated Via Dall-E</figcaption></figure>
Cherry Cola takes the classic Coca-Cola to a new level with a splash of cherry flavor. This soda combines the familiar cola taste with a sweet and fruity cherry twist, making it a refreshing alternative to your usual fizzy drink. It&#8217;s particularly great for those who enjoy a bit of fruitiness in their refreshments. Whether it&#8217;s a hot summer day or a party mixer, Cherry Cola can add that extra zing to your sip!
Seaweed Flavor Lays
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25020422/image-190-1024x585.png" alt="" class="wp-image-307896" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25020422/image-190-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25020422/image-190-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25020422/image-190-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25020422/image-190-1536x878.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25020422/image-190.png 1792w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Seaweed-flavored Lays are known for packing an Umami punch. Image Generated Via Dall-E</figcaption></figure>
If you're up for a snack that's crunchy and packs a flavor punch, Seaweed Flavor Lays might just be your next go-to. Popular in many Asian countries like Thailand, these chips offer a unique umami taste of the ocean. The salty seaweed is a stark contrast to the plain potato, creating a snack that's both bold and addictive. It&#8217;s a daring choice for those looking to explore international flavors in familiar formats.
Snickers Almond
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25014731/image-187-1024x585.png" alt="" class="wp-image-307855" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25014731/image-187-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25014731/image-187-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25014731/image-187-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25014731/image-187-1536x878.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25014731/image-187.png 1792w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Almond Snickers is great if you want a break from the usual peanut variety. Image Generated Via Dall-E</figcaption></figure>
Love Snickers but looking for a nuttier experience? Snickers Almond replaces the classic peanuts with roasted almonds, offering a crunchier texture and a slightly more refined taste. The almonds add a new depth to the chocolate, nougat, and caramel ensemble, making it a sophisticated take on the traditional candy bar. This alternative could become a new favorite for those who appreciate a richer, nuttier snack.
Wasabi Peas
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25014724/image-186-1024x585.png" alt="" class="wp-image-307854" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25014724/image-186-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25014724/image-186-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25014724/image-186-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25014724/image-186-1536x878.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25014724/image-186.png 1792w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Spicy wasabi peas are a great spicy snack but can also act as a palate cleanser. Image Generated Via Dall-E</figcaption></figure>
For those who like their snacks with a bit of a kick, Wasabi Peas are the perfect fiery alternative. These crunchy green peas are coated in a sharp wasabi paste that can clear your sinuses and tantalize your taste buds in one go. Often used as a zesty snack or a palate cleanser at sushi restaurants, they're great for anyone who enjoys a spicy challenge. Dive in if you dare!
Read Next: <a href="https://www.benzinga.com/news/24/04/38357333/elon-musk-reacts-to-tucker-carlson-saying-theres-ton-of-evidence-that-aliens-live-among-us-with-6000?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Reacts To Tucker Carlson Saying There&#8217;s &#8216;Ton Of Evidence&#8217; That Aliens Live Among Us: &#8216;With 6000 Satellites Orbiting Earth, I Think I Would Know&#8217;</a>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Entertainment

Matcha Kit Kat, Cherry Cola And More: Are You Adventurous Enough To Try These 5 Variations Of Your Favorite Snack?

Anywhere Real Estate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOUS#NYSE">HOUS</a>) reported quarterly losses of $(0.91) per share which missed the analyst consensus estimate of $(0.68) by 33.82 percent. The company reported quarterly sales of $1.126 billion which missed the analyst consensus estimate of $1.152 billion by 2.25 percent. This is a 0.44 percent decrease over sales of $1.131 billion the same period last year.

Earnings

Earnings Misses

Anywhere Real Estate Q1 2024 GAAP EPS $(0.91) Misses $(0.68) Estimate, Sales $1.126B Miss $1.152B Estimate

EMCOR Group Increases 2024 Revenue Guidance Range From $13.5B-$14B To $14B-$14.5B (Est $13.705B), EPS Guidance Range From $14.00-$15.00 To $15.50-$16.50 (Est $14.48)

Susquehanna analyst Bascome Majors maintains Westinghouse Air Brake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAB#NYSE">WAB</a>) with a Positive and raises the price target from $160 to $190.

Price Target

Analyst Ratings

Susquehanna Maintains Positive on Westinghouse Air Brake, Raises Price Target to $190

Lincoln Electric Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LECO#NASDAQ">LECO</a>) reported quarterly earnings of $2.23 per share which beat the analyst consensus estimate of $2.17 by 2.76 percent. This is a 4.69 percent increase over earnings of $2.13 per share from the same period last year. The company reported quarterly sales of $981.197 million which missed the analyst consensus estimate of $1.039 billion by 5.59 percent. This is a 5.56 percent decrease over sales of $1.039 billion the same period last year.

Earnings Beats

LECO

Lincoln Electric Holdings Q1 2024 Adj EPS $2.23 Beats $2.17 Estimate, Sales $981.197M Miss $1.039B Estimate

Shyft Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHYF#NASDAQ">SHYF</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.17) by 76.47 percent. This is a 133.33 percent decrease over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $197.889 million which beat the analyst consensus estimate of $184.275 million by 7.39 percent. This is a 18.71 percent decrease over sales of $243.439 million the same period last year.

Shyft Group Q1 2024 Adj EPS $(0.04) Beats $(0.17) Estimate, Sales $197.889M Beat $184.275M Estimate

FTI Consulting (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCN#NYSE">FCN</a>) reported quarterly earnings of $2.23 per share which beat the analyst consensus estimate of $1.87 by 19.25 percent. This is a 66.42 percent increase over earnings of $1.34 per share from the same period last year. The company reported quarterly sales of $928.55 million which beat the analyst consensus estimate of $901.93 million by 2.95 percent. This is a 15.10 percent increase over sales of $806.71 million the same period last year.

FTI Consulting Q1 EPS $2.23 Beats $1.87 Estimate, Sales $928.55M Beat $901.93M Estimate

Imax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IMAX#NYSE">IMAX</a>) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $0.10 by 50 percent. This is a 6.25 percent decrease over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $79.12 million which beat the analyst consensus estimate of $78.18 million by 1.21 percent. This is a 9.00 percent decrease over sales of $86.95 million the same period last year.

IMAX

Imax Q1 Adj EPS $0.15 Beats $0.10 Estimate, Sales $79.12M Beat $78.18M Estimate

Intevac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVAC#NASDAQ">IVAC</a>) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.17) by 41.18 percent. This is a 37.5 percent increase over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $9.631 million which beat the analyst consensus estimate of $6.500 million by 48.17 percent. This is a 16.56 percent decrease over sales of $11.542 million the same period last year.

IVAC

Intevac Q1 2024 Adj EPS $(0.10) Beats $(0.17) Estimate, Sales $9.631M Beat $6.500M Estimate

MORF

Morphic Therapeutic Ended First Quarter With $658.8M In Cash, Cash Equivalents, And Marketable Securities; Cash Runway Into Second Half Of 2027

EMCOR Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EME#NYSE">EME</a>) reported quarterly earnings of $4.17 per share which beat the analyst consensus estimate of $2.84 by 46.83 percent. The company reported quarterly sales of $3.430 billion which beat the analyst consensus estimate of $3.224 billion by 6.40 percent. This is a 18.69 percent increase over sales of $2.890 billion the same period last year.

EMCOR Group Q1 2024 GAAP EPS $4.17 Beats $2.84 Estimate, Sales $3.430B Beat $3.224B Estimate

Susquehanna analyst Biju Perincheril maintains Range Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) with a Neutral and raises the price target from $36 to $38.

Susquehanna Maintains Neutral on Range Resources, Raises Price Target to $38

Hertz Global Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) reported quarterly losses of $(1.28) per share which missed the analyst consensus estimate of $(0.44) by 190.91 percent. This is a 428.21 percent decrease over earnings of $0.39 per share from the same period last year. The company reported quarterly sales of $2.08 billion which beat the analyst consensus estimate of $2.04 billion by 1.96 percent. This is a 1.61 percent increase over sales of $2.05 billion the same period last year.

Hertz Global Holdings Q1 Adj EPS $(1.28) Misses $(0.44) Estimate, Sales $2.08B Beat $2.04B Estimate

Morphic Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MORF#NASDAQ">MORF</a>) reported quarterly losses of $(0.91) per share which beat the analyst consensus estimate of $(0.94) by 3.19 percent. This is a 1.11 percent decrease over losses of $(0.90) per share from the same period last year.

Morphic Holding Q1 2024 GAAP EPS $(0.91) Beats $(0.94) Estimate

Processa Pharmaceuticals Inc (PCSA) is up 2.99% today. PCSA has an Overall Score of 40. Find out what this means to you and get the rest of the rankings on PCSA!See Full PCSA ReportPCSA stock closed at $2.34 and is up $0.07 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as

Processa Pharmaceuticals Inc (PCSA) Up 2.99% in Premarket Trading

Processa Pharmaceuticals Inc (PCSA) is lower by Monday morning, with the stock declining -4.53% in pre-market trading to 2.32. PCSA's short-term technical score of 2 indicates that the stock has traded less bullishly over the last month than 98% of stocks on the market. In the Biotechnology industry, which ranks 117 out of

Premarket Mover: Processa Pharmaceuticals Inc (PCSA) Down 4.53%

Processa Pharmaceuticals regains compliance with Nasdaq minimum bid price rule

Processa Pharmaceuticals (PCSA) has released an update. Processa Pharmaceuticals, Inc. has successfully regained compliance with NASDAQ's minimum c...

Processa Pharmaceuticals Secures NASDAQ Listing Compliance

The market has been neutral on Processa Pharmaceuticals Inc (PCSA)  stock recently. PCSA gets a Neutral score from InvestorsObserver Stock Sentiment Indicator. Processa Pharmaceuticals Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on PCSA!See Full PCSA ReportWhat is

What is the Market's View on Processa Pharmaceuticals Inc (PCSA) Stock's Price and Volume Trends Friday?

Processa Pharmaceuticals Inc (PCSA) is around the bottom of the Biotechnology industry according to InvestorsObserver. PCSA received an overall rating of 39, which means that it scores higher than 39 percent of all stocks. Processa Pharmaceuticals Inc also achieved a score of 29 in the Biotechnology industry, putting it ab

Should You Sell Processa Pharmaceuticals Inc (PCSA) in Biotechnology Industry?

Processa Pharmaceuticals Inc (PCSA) is near the middle in its sector according to InvestorsObserver.PCSA gets an overall rating of 5. That means it scores higher than 5% of stocks.Processa Pharmaceuticals Inc gets a 39 rank in the Healthcare sector. Healthcare is number 2 out of 11 sectors. PCSA has an Overall Score of 5.

Will Processa Pharmaceuticals Inc (PCSA) Lag the Rest of the Stocks in the Healthcare Sector?

Processa Pharmaceuticals Inc (PCSA) is higher by Wednesday morning, with the stock rising 2.59% in pre-market trading to 2.38. PCSA's short-term technical score of 11 indicates that the stock has traded less bullishly over the last month than 89% of stocks on the market. In the Biotechnology industry, which ranks 85 out of

Premarket Mover: Processa Pharmaceuticals Inc (PCSA) Up 2.59%

Processa Pharmaceuticals Inc (PCSA) stock is up 21.70% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator. Processa Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on PCSA!See Full PCSA ReportWhat is Stock Sentiment?

Processa Pharmaceuticals Inc (PCSA) Stock: What Does the Chart Say Monday?

Processa Pharmaceuticals, Inc. (PCSA) has disclosed a new risk, in the Accounting & Financial Operations category. Processa Pharmaceuticals, Inc. c...

Processa Pharmaceuticals' Future in Jeopardy: A Dive into Its Financial Crisis and Industry Risks

Press Releases

Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses